High-than-average fiber consumption does not affect results of wheat bran fiber trial

November 05, 2002

The higher-than-average amount of dietary fiber consumed by participants in the Wheat Bran Fiber (WBF) trial even before they began taking fiber supplements did not account for the results of the trial, which found that fiber intake does not affect the recurrence rate of polyps in the colon. This new analysis appears in the November 6 issue of the Journal of the National Cancer Institute.

Anecdotal evidence has suggested that people who eat high-fiber diets have a lower incidence of colorectal cancer. The WBF trial compared the recurrence rate of adenomatous polyps (abnormal growths in the colon that are considered precursors of colon cancer) among people who were randomly assigned to receive a high-fiber dietary supplement (13.5 g/day) versus a low-fiber dietary supplement (2.0 g/day). The investigators found no difference in the recurrence rate of polyps between the two groups.

But because participants in the WBF trial consumed higher-than-average amounts of fiber compared with the general U.S. population (17.5 grams/day versus 14.8 grams/day), some scientists suggested that these participants had adequate protection from colorectal cancer recurrence even without the addition of a high-fiber supplement. In other words, the beneficial effects of supplemental fiber might be apparent only in participants who had lower baseline fiber intakes.

To see whether this was the case, Elizabeth T. Jacobs, Ph.D., of the Arizona Cancer Center, and her coworkers separated the participants into four groups based on their baseline fiber consumption and calculated the risk of polyp recurrence in each group. They also looked at the effect of baseline intake of fiber from specific food sources on polyp recurrence.

Baseline fiber intake did not appear to be associated with polyp recurrence. There was also no association between baseline intake of fiber from the three leading sources of dietary fiber (fruits; breads, cereals, and crackers; and vegetables) and polyp recurrence. Moreover, baseline fiber intake had no effect on polyp recurrence within each treatment group.
Contact: Rob Raine, Arizona Cancer Center, 520-626-4413; fax: 520-626-8606, rraine@azcc.arizona.edu.

Jacobs E, Giuliano A, Roe D, Guillén-Rodruiguez J, Alberts D, Martinez M. Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial. J Natl Cancer Inst 2002;94:1620-5.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.